IP Verse

Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same

Patent No. EP3823631 (titled "Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same") was filed by Astrazeneca on Jul 18, 2019. The application was issued on May 20, 2026.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BUSSE & BUSSE PATENT UND RECHTSANWALTE PARTNERSCHAFT MBBMay 20, 2026BUSSE & BUSSE
AWA DENMARKMay 20, 2026AWA DENMARK
GENERICS UKMay 20, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3823631

ASTRAZENECA
Application Number
EP19759294A
Filing Date
Jul 18, 2019
Status
Granted And Under Opposition
Apr 17, 2026
Publication Date
May 20, 2026
External Links
Slate, Register , Google Patents